| Date Checked | 2025-12-21 23:42:09 |
|---|
| Graham Number | (PB)16.95 vs (PE)22.80 |
|---|
| Over / Under Value Percentage | 26.29% vs -8.19% |
|---|
| Dividend Yield | 0.00% |
|---|
| Dividend Date | None |
|---|
| Symbol | CPRX |
|---|
| AssetType | Common Stock |
|---|
| Name | Catalyst Pharmaceuticals Inc |
|---|
| Description | Catalyst Pharmaceuticals, Inc. is a prominent commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida, specializing in the development and commercialization of innovative therapies for rare neuromuscular and chronic neurological disorders. With a strong emphasis on addressing critical unmet medical needs, Catalyst's targeted treatment portfolio is designed to significantly improve the quality of life for patients suffering from debilitating conditions often neglected by traditional pharmaceutical approaches. The company's strategic commitment to advancing medical science and enhancing patient outcomes positions it as a key player in the dynamic landscape of rare disease therapeutics, making it an attractive consideration for institutional investors seeking impactful investments in healthcare innovation. |
|---|
| CIK | 1369568 |
|---|
| Exchange | NASDAQ |
|---|
| Currency | USD |
|---|
| Country | USA |
|---|
| Sector | HEALTHCARE |
|---|
| Industry | BIOTECHNOLOGY |
|---|
| Address | 355 ALHAMBRA CIRCLE, CORAL GABLES, FL, UNITED STATES, 33134 |
|---|
| OfficialSite | https://catalystpharma.com |
|---|
| FiscalYearEnd | December |
|---|
| LatestQuarter | 2025-09-30 |
|---|
| MarketCapitalization | 2839276000 |
|---|
| EBITDA | 296569000 |
|---|
| PERatio | 13.51 |
|---|
| PEGRatio | 0 |
|---|
| BookValue | 7.47 |
|---|
| DividendPerShare | None |
|---|
| EPS | 1.71 |
|---|
| RevenuePerShareTTM | 4.757 |
|---|
| ProfitMargin | 0.376 |
|---|
| OperatingMarginTTM | 0.447 |
|---|
| ReturnOnAssetsTTM | 0.177 |
|---|
| ReturnOnEquityTTM | 0.275 |
|---|
| RevenueTTM | 578196000 |
|---|
| GrossProfitTTM | 480674000 |
|---|
| DilutedEPSTTM | 1.71 |
|---|
| QuarterlyEarningsGrowthYOY | 0.2 |
|---|
| QuarterlyRevenueGrowthYOY | 0.153 |
|---|
| AnalystTargetPrice | 34.86 |
|---|
| AnalystRatingStrongBuy | 1 |
|---|
| AnalystRatingBuy | 6 |
|---|
| AnalystRatingHold | 0 |
|---|
| AnalystRatingSell | 0 |
|---|
| AnalystRatingStrongSell | 0 |
|---|
| TrailingPE | 13.51 |
|---|
| ForwardPE | 10.19 |
|---|
| PriceToSalesRatioTTM | 4.911 |
|---|
| PriceToBookRatio | 3.021 |
|---|
| EVToRevenue | 3.62 |
|---|
| EVToEBITDA | 7.06 |
|---|
| Beta | 0.688 |
|---|
| 52WeekHigh | 26.58 |
|---|
| 52WeekLow | 19.05 |
|---|
| 50DayMovingAverage | 21.41 |
|---|
| 200DayMovingAverage | 22.04 |
|---|
| SharesOutstanding | 122912000 |
|---|
| SharesFloat | 115293000 |
|---|
| PercentInsiders | 6.294 |
|---|
| PercentInstitutions | 87.123 |
|---|
| ExDividendDate | None |
|---|
| etoro | 1 |
|---|
| dateChecked | 2025-12-21 23:42:09 |
|---|
| fresh | 1 |
|---|